Videos

Erica L. Mayer, MD, MPH, assistant professor of medicine at Harvard Medical School and Dana-Farber Cancer Institute, describes studies involving tivozanib, a potent VEGF receptor tyrosine kinase inhibitor.

The pace of discovery in breast cancer research has been brisk in the past year, leading not only to the approval of several new therapies but also to clinical trial results with the potential to change practice.

Despite the trend toward targeted therapies, cytotoxic drugs remain a mainstay of metastatic breast cancer treatment, and new therapies in that class are needed.

Jeffrey N. Weitzel, MD, from City of Hope, discusses the need to develop combination strategies for patients with breast cancer, in order to overcome the resistance.

Older women with breast cancer who prefer less input from their physician when deciding on treatment are less likely to receive chemotherapy than women who prefer to rely on their physician to a greater degree, a recent study has found.

José Baselga, MD, PhD, from Memorial Sloan-Kettering Cancer Center, discusses the investigation of pan-PI3K inhibitors for patients with metastatic breast cancer.

Pertuzumab, a new HER2-positive breast cancer drug, is being launched at a 31% premium to the price of trastuzumab.

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses a phase II trial that examined GRN1005 in patients with brain metastases from breast cancer.

Hope S. Rugo, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, previews the 2012 San Antonio Breast Cancer Symposium program.

Novel combinations of hormonal therapies with targeted agents show promise for improved outcomes and are likely to become part of a new paradigm for managing patients.

Investigators have documented a significant 4.5-month median overall survival advantage with lapatinib combined with trastuzumab in women with heavily pretreated HER2-positive metastatic breast cancer.

Terry P. Mamounas, MD, MPH, from Aultman Hospital Cancer Center, discusses the administration of neoadjuvant chemotherapy for patients with early-stage breast cancer.

Six cycles of doxorubicin and cyclophosphamide or single-agent paclitaxel do not lead to a superior outcome versus four cycles as adjuvant chemotherapy in women with resected primary breast cancer.

An overview of studies looking at the potential of osteoclast inhibitors in the prevention of breast cancer recurrences in the adjuvant setting.

Sramila Aithal, MD, from Cancer Treatment Centers of America, discusses the HERceptin Adjuvant (HERA) trial that examined adjuvant therapy with trastuzumab for women with HER2-positive early breast cancer.

Massimo Cristofanilli, MD, from Fox Chase Cancer Center, discusses the investigation of small-molecule ALK inhibitors to treat patients with inflammatory breast cancer.

Pamela Munster, MD, from UCSF Helen Diller Family Comprehensive Cancer Center, discusses results from a phase II study that examined vorinostat in combination with tamoxifen for endocrine therapy-resistant breast cancer.

A thorough examination of emerging strategies for the treatment of breast cancer, as well as the clinical data underlying new and existing options, will form the cornerstone of the 9th Annual School of Breast Oncology.